Oral GLP-1 Medications: FDA-Approved Pills in 2026

Which oral GLP-1 medicines are FDA-approved?

As of August 8, 2026, FDA materials identify four branded oral GLP-1 products relevant to common searches: Wegovy tablets, Foundayo, Rybelsus, and Ozempic tablets. Wegovy tablets, Rybelsus, and Ozempic tablets contain semaglutide. Foundayo contains orforglipron, a different GLP-1 receptor agonist. The shared “GLP-1” description does not make these products versions of one another.

The brand name and FDA-approved indication are essential. Wegovy tablets and Foundayo are approved for chronic weight management in adults who meet label criteria. Rybelsus and Ozempic tablets are approved for adults with type 2 diabetes. A search for an “oral GLP-1” can therefore lead to medicines intended for different conditions, even when their names or ingredients seem related.

Wegovy tablets and the weight-management indication

Wegovy tablets are an oral form of semaglutide approved in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight and at least one weight-related condition. The approval letter also includes reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.

That cardiovascular indication refers to a defined population and named outcomes in the FDA materials. It is not a general claim that the product prevents heart problems for everyone. Wegovy injection has additional label content that does not automatically apply to the tablet. Use the exact dosage form and current label when checking an indication, warning, or administration question.

Foundayo and orforglipron

FDA approved Foundayo, whose active ingredient is orforglipron, on April 1, 2026. Its approved use is chronic weight management, together with a reduced-calorie diet and increased physical activity, for adults with obesity or adults with overweight and at least one weight-related condition. The approval made it a current oral option rather than an investigational product.

Orforglipron is not semaglutide. Results, precautions, contraindications, interactions, and instructions attached to one active ingredient should not be copied to the other. This page does not rank Foundayo against Wegovy tablets or predict which one would work better for an individual. Those comparisons require clinical history, current labeling, and a licensed prescriber.

Rybelsus and Ozempic tablets are diabetes products

The current FDA label covers Rybelsus and Ozempic tablets as oral semaglutide products for adults with type 2 diabetes. Their labeled uses include improving blood glucose along with diet and exercise and reducing major cardiovascular-event risk in certain adults with type 2 diabetes. The label does not approve these tablet brands for chronic weight management.

This distinction prevents a common mistake: treating every semaglutide tablet as the same product. Wegovy tablets, Rybelsus, and Ozempic tablets share an active ingredient, but they do not share every approved use, strength, or instruction. They should not be converted or substituted milligram for milligram. A pharmacist or prescriber can identify the exact product on a prescription and explain the current label.

How oral does and does not simplify treatment

A tablet avoids an injection, but “oral” does not mean over the counter, low risk, or free of timing requirements. These are prescription medicines with product-specific administration instructions. Some oral GLP-1 products have instructions about food, water, and other medicines, while another product may have different requirements. The controlling source is the label for the exact brand and dosage form.

This article intentionally does not reproduce dose schedules or offer instructions for starting, stopping, or switching medicines. Those details can change and may interact with diabetes treatment, other prescriptions, planned procedures, pregnancy, and medical history. If a tablet is being considered, bring the exact brand name and medication list to a clinician or pharmacist rather than applying instructions from a different GLP-1 product.

Safety, compounded products, and changing evidence

FDA-approved does not mean appropriate for every person. Each label contains contraindications, warnings, adverse reactions, and interaction information. Product identity also matters when reading online claims: a compounded product is not an FDA-approved generic version, and an ingredient sold as a research chemical is not an approved oral GLP-1 medicine. FDA has published concerns about unapproved GLP-1 products used for weight loss.

Approval status and labels can change. Check the source date and the exact product before relying on a summary. This page is an editorial explanation of current FDA documents, not a treatment recommendation and not a substitute for the prescribing information. Questions about eligibility, symptoms, side effects, missed doses, or changing medicines belong with a licensed clinician or pharmacist.

Oral GLP-1 Medications: FDA-Approved Pills in 2026 questions